07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Bioniche cancer news

Bioniche reached a settlement with dissident shareholders, former Biovail Corp. CEO William Wells and former Biovail SVP Greg Gubitz. Under the settlement, Gubitz and Wells agreed to subscribe for an aggregate of C$250,000 ($240,245) of...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Bioniche cancer news

Bioniche said that dissident shareholders are trying to set a date for a shareholder meeting in August. Bioniche said the move constitutes an "inappropriate and invalid" step given that the company's scheduled annual meeting is...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Bioniche cancer news

Bioniche said it will not call a shareholder meeting despite the request of dissident shareholders. The company said its legal counsel advised that the request does not constitute a valid shareholder requisition. Bioniche said it...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Company News

Bioniche cancer news

Bioniche responded to an April 19 letter from former Biovail Corp. CEO William Wells and former Biovail SVP Greg Gubitz, who represent a group of shareholders that together own over 5% of Bioniche shares. In...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

Pimavanserin: Additional Phase III data

Additional data from the double-blind, North American Phase III ACP-103-020 trial in 199 patients with PDP showed that once-daily 40 mg oral pimavanserin met the secondary endpoints of improving CGI-S scores (p<0.001) and CGI-I responder...
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Maple leaf windfall

The $510.3 million Gilead Sciences Inc. will pay to take out YM BioSciences Inc. puts the deal in the top five transactions involving a Canadian biopharma company in the past five years. Gilead (NASDAQ:GILD) will...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Pimavanserin: Phase III data

Top-line data from the double-blind, North American Phase III ACP-103-020 trial in 199 patients with PDP showed that once-daily 40 mg oral pimavanserin met the primary endpoint of improving antipsychotic efficacy as measured by the...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Bupropion regulatory update

Germany's IQWiG said in a cost-benefit assessment that the cost of each of 4 antidepressants - bupropion, duloxetine, mirtazapine and venlafaxine - is above the threshold determined by IQWiG to be cost-effective. However, IQWiG conceded...
01:56 , Nov 28, 2012 |  BC Extra  |  Clinical News

Acadia jumps on Phase III pimavanserin data

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $3.13 (136%) to $5.43 on Tuesday after reporting that once-daily 40 mg oral pimavanserin as an adjunct to stable doses of existing anti-Parkinson's therapy met the primary endpoint in the...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Wellbutrin XL bupropion regulatory update

Valeant disclosed on its conference call to discuss 3Q12 earnings that it submitted a Citizen's Petition to FDA arguing that all generic versions of antidepressant 300 mg Wellbutrin XL bupropion should not be marketed until...